These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 8832033)

  • 1. Proposal on RBC transfusion guidelines for BMT.
    Aoki Y
    Bone Marrow Transplant; 1996 Jul; 18(1):261. PubMed ID: 8832033
    [No Abstract]   [Full Text] [Related]  

  • 2. Embryonic stem cells: good to the bone?
    Eisenstein M
    Lab Anim (NY); 2004 May; 33(5):10. PubMed ID: 15141230
    [No Abstract]   [Full Text] [Related]  

  • 3. [Study on nonmyeloablative allogeneic bone marrow transplantation in the treatment of L615 leukemia mice].
    Xu KL; Ju JP; Pan XY; Du B; Li ZY; Lu QX
    Zhonghua Xue Ye Xue Za Zhi; 2003 Jul; 24(7):372-5. PubMed ID: 12941194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allogeneic peripheral blood hematopoietic stem cell transplantation: guidelines for red blood cell immuno-hematological assessment and transfusion practice.Société Française de Greffe de Moelle.
    Lapierre V; Kuentz M; Tiberghien P
    Bone Marrow Transplant; 2000 Mar; 25(5):507-12. PubMed ID: 10713627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T cell-depleted granulocyte colony-stimulating factor (G-CSF) modified allogenic bone marrow transplantation for hematological malignancy improves graft CD34+ cell content but is associated with delayed pancytopenia.
    Mavroudis DA; Read EJ; Molldrem J; Raptis A; Plante M; Carter CS; Phang S; Dunbar CE; Barrett AJ
    Bone Marrow Transplant; 1998 Mar; 21(5):431-40. PubMed ID: 9535034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapamycin and T cell costimulatory blockade as post-transplant treatment promote fully MHC-mismatched allogeneic bone marrow engraftment under irradiation-free conditioning therapy.
    Wu T; Sozen H; Luo B; Heuss N; Kalscheuer H; Lan P; Sutherland DE; Hering BJ; Guo Z
    Bone Marrow Transplant; 2002 Jun; 29(12):949-56. PubMed ID: 12098061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of graft-versus-host disease by intra-bone marrow injection of donor T cells.
    Fukui J; Inaba M; Ueda Y; Miyake T; Hosaka N; Kwon AH; Sakaguchi Y; Tsuda M; Omae M; Kamiyama Y; Ikehara S
    Stem Cells; 2007 Jun; 25(6):1595-601. PubMed ID: 17446564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amotosalen-treated donor T cells have polyclonal antigen-specific long-term function without graft-versus-host disease after allogeneic bone marrow transplantation.
    Hossain MS; Roback JD; Lezhava L; Hillyer CD; Waller EK
    Biol Blood Marrow Transplant; 2005 Mar; 11(3):169-80. PubMed ID: 15744235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A metalloproteinase inhibitor prevents acute graft-versus-host disease while preserving the graft-versus-leukaemia effect of allogeneic bone marrow transplantation.
    Hattori K; Hirano T; Miyajima H; Yamakawa N; Ikeda S; Yoshino K; Tateno M; Oshimi K; Kayagaki N; Yagita H; Okumura K
    Br J Haematol; 1999 Apr; 105(1):303-12. PubMed ID: 10233398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new strategy for treatment of malignant tumor: intra-bone marrow-bone marrow transplantation plus CD4- donor lymphocyte infusion.
    Suzuki Y; Adachi Y; Minamino K; Zhang Y; Iwasaki M; Nakano K; Koike Y; Ikehara S
    Stem Cells; 2005 Mar; 23(3):365-70. PubMed ID: 15749931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transfusion management of sickle cell patients during bone marrow transplantation with matched sibling donor.
    McPherson ME; Anderson AR; Haight AE; Jessup P; Castillejo MI; Hillyer CD; Josephson CD
    Transfusion; 2009 Sep; 49(9):1977-86. PubMed ID: 19453984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen.
    Pelot MR; Pearson DA; Swenson K; Zhao G; Sachs J; Yang YG; Sykes M
    Biol Blood Marrow Transplant; 1999; 5(3):133-43. PubMed ID: 10392959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of different busulfan analogues for depletion of hematopoietic stem cells and promotion of donor-type chimerism in murine bone marrow transplant recipients.
    Westerhof GR; Ploemacher RE; Boudewijn A; Blokland I; Dillingh JH; McGown AT; Hadfield JA; Dawson MJ; Down JD
    Cancer Res; 2000 Oct; 60(19):5470-8. PubMed ID: 11034090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of acute graft-vs-host disease by a single low-dose cyclophosphamide injection following allogeneic bone marrow transplantation.
    Prigozhina TB; Elkin G; Khitrin S; Slavin S
    Exp Hematol; 2008 Dec; 36(12):1750-9. PubMed ID: 18809241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term observation after simultaneous lung and intra-bone marrow-bone marrow transplantation.
    Kaneda H; Adachi Y; Saito Y; Ikebukuro K; Machida H; Suzuki Y; Minamino K; Zhang Y; Iwasaki M; Nakano K; Koike Y; Wang J; Imamura H; Ikehara S
    J Heart Lung Transplant; 2005 Sep; 24(9):1415-23. PubMed ID: 16143265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Experimental study on NK cells promoting donor marrow engraftment and hematopoietic reconstitution after MHC haploidentical BMT in mice].
    Wang CY; Guo KY; Wu BY; Wu LX; Jiang ZY; Pan XH
    Zhonghua Xue Ye Xue Za Zhi; 2004 May; 25(5):290-2. PubMed ID: 15182539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Study of experimental mixed bone marrow transplantation].
    Luo H; Yang P; He F
    Zhonghua Xue Ye Xue Za Zhi; 1998 Aug; 19(8):418-21. PubMed ID: 11189509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and impact of donor-type red blood cell transfusion before allogeneic peripheral blood progenitor cell transplantation with major ABO mismatch.
    Scholl S; Klink A; Mügge LO; Schilling K; Höffken K; Sayer HG
    Transfusion; 2005 Oct; 45(10):1676-83. PubMed ID: 16181220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
    Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
    J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic blood stem cell and bone marrow transplantation for acute myelogenous leukemia and myelodysplasia: influence of stem cell source on outcome.
    Russell JA; Larratt L; Brown C; Turner AR; Chaudhry A; Booth K; Woodman RC; Wolff J; Valentine K; Stewart D; Ruether JD; Ruether BA; Klassen J; Jones AR; Gyonyor E; Egeler M; Dunsmore J; Desai S; Coppes MJ; Bowen T; Anderson R; Poon MC
    Bone Marrow Transplant; 1999 Dec; 24(11):1177-83. PubMed ID: 10642805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.